🌕 Gate Square · Mid-Autumn Creator Incentive Program is Now Live!
Share your creations with trending topics and get a chance to split $5,000 in rewards! 🎁
👉 Join now: https://www.gate.com/campaigns/1953
💡 How to Join:
1️⃣ Post with the hashtag #Gate Square Mid Autumn Creator Incentive# .
2️⃣ Your content should follow the daily trending topics posted by [Gate _Square], and include both hashtags.
3️⃣ The more posts, higher quality, and greater engagement — the bigger your rewards! 🚀
💰 Creator Rewards:
🏆 Top 1: Bulgari Mid-Autumn Gift Box + $100 Futures Voucher + $100 GT
🥈 Top 2: Bulgari
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.